雷珠单抗注射液联合白内障超声乳化治疗白内障合并糖尿病性黄斑水肿的临床研究

Clinical Study of Leizumab Injection Combined with Cataract Phacoemulsification in Treatment of Cataract Complicated with Diabetes Macular Edema

目的分析对白内障合并糖尿病性黄斑水肿(DME)应用雷珠单抗注射液与白内障超声乳化(PHACO+IOL)联合治疗的效果。方法选取本院2022年3月—2023年3月收治的白内障并DME患者84例,随机将其均分为两组,对照组采用PHACO+IOL治疗,观察组采用雷珠单抗注射液与PHACO+IOL联合治疗,对比分析两组治疗前后眼压与BCVA以及CMT水平。结果治疗后,两组眼压均有所下降,BCVA水平均有所提升,观察组眼压与对照组不存在明显差异(P>0.05),观察组BCVA明显高于对照组(P<0.05)。术后1个月、3个月、6个月,两组CMT水平明显下降,相比于对照组,观察组更低(P<0.05)。对照组并发症发生率为21.43%,观察组为4.76%,观察组明显更低(P<0.05)。结论在白内障并DME患者临床治疗期间,应用雷珠单抗注射液与白内障超声乳化联合治疗效果理想,可使患者CMT得到有效改善,矫正患者视力,具备较高的推广可行性。

Objective To analyze effect of Leizumab injection combined with phacoemu lsification(PHACO+IOL)for cataract with diabetes macular edeMA(DME).Methods The paper chose 84 patients with cataracts and DME in our hospital from March 2022 to March 2023,and divided them into two groups randomly:control group(42 cases,treated with PHACO+IOL)and observation group(42 cases,with combination of ranibizumab injection and PHACO+IOL).Intraocular pressure,BCVA,and CMT levels before and after treatment were compared and analyzed between two groups.Results After treatment,both groups showed decrease in intraocular pressure and increase in BCVA levels.There was no significant difference in intraocular pressure between observation group and control group(P>0.05),while BCVA in observation group was significantly higher than control group(P<0.05).At 1,3,and 6 months after surgery,levels of CMT in both groups significantly decreased,observation group had lower levels than control group,(P<0.05).Incidence of complications in observation group(4.76%)was significantly lower than control group(21.43%),(P<0.05).Conclusion Combination of ranibizumab injection and cataract phacoemulsification can achieve ideal effect in clinical treatment of cataract patients with DME,can improve CMT,correct vision of patients effectively,which has high promotional feasibility.